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Introduction: The epidemiology of Clostridium difficile infection (CDI) has changed in the last
two  decades. There is a lack of information regarding incidence and severity of CDI, espe-
cially in the developing world.
Methods: This was a retrospective and observational study from four hospitals of three Mex-
ican  cities. Patients were diagnosed with CDI when presented with loose stools and had at
least one of the following tests positive: toxins assay, real-time PCR, or an endoscopic image
compatible with pseudomembranous colitis. CDI was classified according to international
guidelines. Demographic and clinical data as well as information regarding total hospital
admissions, total length-of-hospital stay, and other variables related to hospitalization were
gathered from the epidemiology and administration departments of each hospital.
Results: A total of 2050 hospital beds were analyzed with 288,171 patients hospitalized accu-
mulating 1,576,446 days of hospitalization during the study period. The average rate of CDI
per  1000 hospital-days was lower than the rates reported in the US and Europe, although
in  2015 CDI rates were almost persistently above the mean rate for the study period. More
than half of PCR positive patients were ribotype 027.
Conclusion: Hospital rates of CDI are increasing in Mexican hospitals with a predominanceby ribotype 027.of  infections caused © 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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say and 192 patients turned out positive (96%); PCR was
performed in 311 and 284 (88.5%) tested positive. Out of those
positive by real time PCR, 145/284 (51.1%) were also positiveb r a z j i n f e c t d i s .
ntroduction
he epidemiology of Clostridium difficile infection (CDI) has
hanged in the last two decades, with an increasing incidence
nd severity of the disease.1,2 In the United States, the burden
f CDI has been estimated to be over 450,000 cases per year3
nd hospitalizations have increased by >200% in recent years.4
Incidence and infection rates have been mainly described
n European countries,5 Australia,6 and in the United States.7
here is a lack of information about incidence and severity of
DI, especially in low and middle income countries around
he globe.8,9 Furthermore, some hypervirulent strains have
een documented in patients from Latin America9 including
exico,8,10 although their clinical relevance is uncertain. The
im of this study was to describe CDI rates and patient’s char-
cteristics from four Mexican hospitals.
ethods
esign  and  participating  healthcare  facilities
his study was retrospective and observational. A total of four
ospitals participated in the study: Hospital Univiersitario
Dr. José Eleuterio González” (HU) a public teaching hospital
ith 500 beds, located in Monterrey, Nuevo León (North-
astern Mexico); Hospital Civil de Guadalajara “Fray Antonio
lcalde” (HCG), which is a public teaching hospital of 1000
eds in Guadalajara, Jalisco (Western Mexico); Hospital Gen-
ral “Manuel Gea Gonzalez” (GEA) a public university hospital
f 250 beds in Mexico City (Central Mexico). These hospi-
als provide medical care to a wide range of population, with
aternity, pediatric, medical, and surgical wards. The fourth
ospital was Instituto Nacional de Cancerología (INCAN)
Central Mexico), a referral cancer hospital for adult patients
ith 170 beds.
iagnosis  and  classification  of  CDI
atients included in the study were adults with a suspected
iagnosis of CDI who reported ≥3 bowel movements with loose
tools (Bristol 5–7) in the preceding 24 h. For CDI confirmation
t least one of the following tests had to be positive: detection
f toxins using the ImmunoCard toxins A&B assay (Merid-
an Bioscience, Cincinnati, OH, USA) in stools, real-time PCR
Cepheid Xpert C. difficile/Epi, Cepheid, Sunnyvale CA) in stools,
r an endoscopic image  consistent with pseudomembranous
olitis. All hospitals used the same diagnostic methods with
he exception of GEA and INCAN where no PCR-testing was
erformed. At the time of the study, none of the hospitals used
lutamate deshidrogenase test (GDH).
CDI was classified as hospital-onset healthcare facility-
ssociated CDI (HO-HCFA) when patients had been in-hospital
or at least 48 h and were CDI free at admission, or as
ommunity-onset health care facility-associated (CO-HCFA)
hen patients were hospitalized for at least 48 h during
he previous 12 weeks at CDI onset.11 Data on community-
cquired CDI was very limited, with no cases included.
reatment failure was defined as persistence of diarrhea after
ve days of treatment.12
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Patient’s  characteristics  and  CDI  rates
The medical records of registered cases of CDI  from January
1, 2011 to December 30, 2015 were reviewed. Information on
demographic and clinical data such as age, gender, comorbidi-
ties, predisposing factors, length-of-hospital stay, colectomy,
and 30-day hospital mortality among others were collected.
Information regarding hospital admissions at each center,
total length-of-hospital stay and other hospital-related vari-
ables were collected from epidemiology and administration
departments in each hospital.
Statistical  analysis
Descriptive statistics were used to analyze the variables. For
continuous variables with normal distribution, mean and
standard deviation were calculated; for those variables with
non-normal distribution, median and range were calculated.
For all other variables, number and percentage, or range, was
calculated as appropriate. Infection rates for 1000 patient-days
and per 100 hospital admissions were calculated. Odds ratio
was calculated using SPSS (version 20.0).
Ethics  approval
The study protocol was reviewed and approved by the Hospital
Civil de Guadalajara (number 034/16) and Instituto Nacional de
Cancerología Institutional Board Review (number REV/41/16).
Results
Demographic  and  clinical  characteristics  of  patients
A total of 487 patients who met  CDI criteria (HU 168, HCG 267,
GEA 30 and INCAN 22) were included, mean age 47.4 ± SD 19.6
years, and a slight predominance of males (Table 1). Almost
half of the patients had between 4 and 6 bowel movements
per day. Abdominal pain was reported by 52% of patients and
45.1% presented fever. Nearly half of the patients were treated
initially with a combination of vancomycin and metronida-
zole (48.2%) and 35.3% with metronidazole alone. The average
length of treatment was 9.7 days, and the mean time between
initiation of treatment and diarrhea disappearance was three
days; for fever remission the average time was 1.3 days.
The overall failure rate was 19.3%, with a 30-day mortality
rate of 18.1%. Attributable mortality was estimated at 9.0%
(Table 1).
CDI  infection
From the 487 patients included, 200 were tested by immunoas-for C. difficile ribotype 027 (detected in the same test) and
139/284 were negative for 027 thus classified as non-027 ribo-
type (Table 1). There were no statistical differences regarding
ClinicalKey.com by Elsevier on March 22, 2018.
8. Elsevier Inc. All rights reserved.
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Table 1 – Characteristics of the 487 patients included and
their outcome charts.
Characteristic Average ± SD (%)
Demographic and clinical data
Age 47.47 ± 19.68
Gender
Male 292 (60.0)
Female 195 (40.0)
Fever 220 (45.1)
Abdominal pain 253 (52.2)
Leucocytes, k/ml 15.11 ± 12.14
Albumin 2.17 ± 0.71
Creatinine 2.10 ± 3.16
Bowel movements per daya
≤3 84 (26.4)
4–6 158 (49.7)
≥7 76 (23.9)
ATLAS score 4.91 + 1.71
0–3 points 41 (18.7)
4–7 points 160 (73.4)
8–10 points 17 (7.8)
Primary diagnosis
Medical 70.0%
Surgical 30.0%
Comorbidities and predisposing risk factors
Total LOS
LOS before diagnosis
LOS after diagnosis
20.19  ± 21.37
13.66 ± 14.96
15.25 ± 15.65
Previous ICU stay 68 (13.9)
Immunosuppression
Invasive mechanical
ventilation
40  (8.2)
Proton pump inhibitors 373 (76.5)
H2 blockers 40 (8.2)
Diagnosis of CDI
Immunoassay for toxins
A/B
192  (39.4)
PCR 284 (58.3)
C. difficile ribotype 027 145/284 (51.1)
C. difficile non-027 ribotype 139/284 (48.9)
Endoscopy
(pseudomembranous colitis)
43  (8.8)
Initial treatment of CDI
Metronidazole 77 (35.3)
Vancomycin 34 (15.7)
Vancomycin + Metronidazole
105  (48.2%)
Fecal microbiota transplant 8 (3.7%)
Rifaximin 1 (0.5)
Colectomy 1 (0.5)
Treatment duration (days) 9.76 ± 4.74
Treatment failurea 42/218 (19.3)
30-day mortality 88 (18.1)
Attributable mortality 44 (9.0)
a Clinical information was not available for all of the patients.
LOS is of particular importance in busy, overcrowded, pub-
lic hospitals.18 The duration of hospital stay was longer aftertreatment failure, 30-day mortality, and colectomy between
patients with 027 or non-027 ribotype (Table 2).
Out of the 487 cases of CDI included, 43 (8.8%) were diag-
nosed in 2012, 22 (4.5%) in 2013, with a sharp increase in 2014
with 121 (24.8%) cases, and 301 (61.8%) in 2015. The mean hos-
pital length-of-stay was 20.1 ± 21.3 (SD) days, with an average
13.6 ± 14.9 (SD) days prior to CDI diagnosis. After CDI diagnosis
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patients had an extra hospital stay of 15.2 ± 15.6 (SD) days
(Table 1).
Hospital  CDI  rates
A combined number of 2050 hospital beds were analyzed, with
a total of 288,171 patients hospitalized accumulating 1,576,446
days of hospital stay during the study period. The average rate
of CDI per 1000 hospital-days was 0.28, and 0.15 cases per 100
hospital admissions. Throughout 2015, CDI rates were almost
persistently above the mean rate for the study period (Fig. 1)
with a remarkable increasing trend. The lowest rates of CDI
were recorded in 2013 with an average of 0.003 cases per 1000
hospital-days compared to 0.34 in 2015. February and April
2015 had the highest CDI rates per 100 admissions, namely
0.83 and 0.87 cases, respectively.
Discussion
CDI is an increasing public health problem in many  regions
of the world.13 Information on CDI hospital rates in middle
and low-income countries in Latin-America, Asia, and East-
ern Europe is limited. Data on microbiology, infection rates,
and clinical characteristicsis are needed in order to better
understand local and regional behavior of these infections.
Implementation of infection control policies in different sett-
ings is also necessary.
In this study, the average rate of CDI was 0.28 per 1000
patient-days. These rates are lower than the 0.6 per 1000
patient-days those reported by Durkins14 et al., in a study
that included 29 hospitals, or the 0.6, 0.8, and 0.9 cases per
1000 patient-days reported in Poland from 2011 through 2013,
respectively.14,15 The reported rates in this series are also
lower than the rates observed in a large European study in
2012–20135 with an average rate of 6.9 cases per 1000 patient
bed-days. It is important to mention that diagnostic methods
used in both studies were different from those used in our
study.
Considering that the CDI rate in 2015 was 0.6 per 1000
hospital-days, and that the current survey showed an increas-
ing trend in the rate of infections, we can speculate that rates
are now similar to the studies mentioned above. The 7-fold
increase in 2015 rates compared to the initial period of the
study was observed in all four participating hospitals.
Murad et al. demonstrated that the use of PCR for detection
of CDI is associated to an overestimation of cases, especially
during outbreaks.16 We consider that this is not the case in
our findings, because PCR test was used only in symptomatic
patients with more  than three loose stools, and at least in one
hospital (INCAN) PCR was not available during the entire study
period.
For CDI cases, length-of-stay (LOS) was similar in the four
participating Institutions. It was not different from those
reported in Madrid, but it was lower than the LOS reported
in Barcelona and Rome between 2011 and 2013.16,17 Thediagnosis than before CDI diagnosis, with no difference in the
total LOS in the participating hospitals despite an increase in
 ClinicalKey.com by Elsevier on March 22, 2018.
18. Elsevier Inc. All rights reserved.
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Table 2 – Comparison of outcomes among patients with ribotype 027 and non-027 ribotype.
Characteristics Ribotype OR  (95% CI) p
027 (N = 145)
n (%)
Non-027 (N = 139)
n (%)
Treatment failure 3  (2.07) 1 (0.72) 2.91 (0.29–28.37) 0.356
30-Day mortality 22 (15) 22 (16) 0.95 (0.50–1.80) 0.878
Attributable
mortality
11 (7.59) 7 (5.04) 1.54 (0.58–4.11) 0.381
Colectomy 2 (1.38) 0 (0) 4.86 (0.23–102.15) 0.308
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dhe number of CDI cases diagnosed during the study. The lat-
er contrasts with the findings in the study by Miller et al.,19
here the total LOS was increased in hospitals with a higher
ate of CDI and even patients without CDI had longer LOS in
ospitals with higher CDI rates; in our study the average global
ospital LOS was 5.7 days at the beginning of the study and
.4 days in 2015.
It should be pointed out that more  than half of the CDI
dentified by PCR were ribotype 027. This percentage is almost
-fold higher than the average 18% reported by Davies5 et al.
n that study, Germany was the country with the highest rate
or ribotype 027 (43%).5 This data may suggest a higher sever-
ty of CDI. The relevant clinical outcomes of CDI in our study
uch as treatment failure or attributable mortality were sim-
lar to other reports.17 In addition, in the current study there
ere no differences between patients infected by ribotype
27 compared to non-027 strains regarding treatment failure,
olectomy, and mortality.
The increasing prevalence of ribotype 027 of C. difficile in
exico has been highlighed in previous reports from two of
he participating hospitals.8,10
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dardized diagnostic algorithms, with diagnosis based on
the positive result of either, one of two laboratory tests,
and to a lesser extend to endoscopic findings. The absence
of a standardized protocol leaves room for false negative
reports, particularly when immunoassay was the only test
used. Although the four Institutions included perform regu-
lar surveillance and have protocols for identification of CDI
patients, variations in reporting between Institutions may
also exist. Another limitation is that not all cases could be
differentiated by a molecular method lacking information
about the possible ribotypes diversity in these hospitals. No
information could be gathered regarding treatment with fidax-
omicin since at present time its distribution is not approved in
Mexico.
Despite the above limitations, we consider that this report
demonstrates the increasing trend of CDI in a middle-income
country in Latin America, and highlights the emergent CDI
problem in different types of public and academic hospitals in
our country. Reporting CDI cases and rates occurring in Mex-
ican hospitals is not mandatory, a phenomenon frequently
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seen in other countries. Therefore, we recommend mandatory
notification of CDI cases to be implemented.
To the best of our knowledge, this is the first multi-
Institutional report on CDI rates in Mexico and Latin-America.
Conclusion
Hospital rates of CDI are increasing in the Mexican hospitals
analyzed in this study. In recent years CDI rates have been
similar to those reported in Europe and in the United States
with a predominance of infections caused by ribotype 027.
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